Medtronic Continues To Run (RNA) Interference With Alnylam
Device firm is upping its investment in biotech drug delivery by expanding its collaboration with Alnylam for development of an RNA-based treatment for Huntington’s disease.
Device firm is upping its investment in biotech drug delivery by expanding its collaboration with Alnylam for development of an RNA-based treatment for Huntington’s disease.